CASRAI Dictionary

Tag: nih grant terminations halted

  • NIH Grant Termination Study: What the Data Show

    Independent tracking studies of the National Institutes of Health’s 2025 grant terminations show the cuts did not fall evenly across the biomedical research portfolio. This NIH grant termination study review of four separate tracking efforts finds early-career investigators, women-led projects, infectious-disease and health-equity research, and a small cluster of NIH institutes and institutions absorbed a disproportionate share of the losses.

    An NIH grant termination study, in this context, is an independent, data-driven analysis — built from crowd-sourced trackers such as Grant Witness and NIH’s own Research Portfolio Online Reporting Tools (RePORTER) — that quantifies which grants the agency cancelled and who held them, because NIH has not published a single consolidated breakdown of its own.

    How independent studies measured the terminations

    NIH has not released an official, comprehensive tally of terminated awards, so researchers and journalists have relied on independent trackers to reconstruct the picture. Four efforts now anchor most public analysis:

    • Fregolent et al. (2026), published in PNAS, matched the crowd-sourced Grant Witness database against NIH RePORTER records for grants cancelled between February and August 2025.
    • Patel, Liu and Jena (2025), published in JAMA Internal Medicine, linked NIH ExPORTER data with the HHS Tracking Accountability in Government Grants System for a narrower 28 February–8 April 2025 window.
    • The Association of American Medical Colleges (AAMC) published a running snapshot of terminations as of 5 May 2025.
    • A PubMed Central review (Faiman et al., 2025) tracked cumulative losses across the calendar year, including clinical-trial detail by disease area.

    Because each study samples a different date range and data source, the headline totals diverge — but the pattern of who was affected is remarkably consistent across all four.

    Which career stages absorbed the deepest cuts

    Training and early-career funding took a disproportionate hit. Under the PNAS analysis, women held 60% of the 530 cancelled grants among assistant professors and doctoral students, while men lost 59% of the 1,410 cancelled grants held by professors and associate professors — meaning losses skewed toward more junior investigators even as senior researchers lost more total dollars.

    Predoctoral and undergraduate pipeline awards were hit hardest of all: women held 58% of cancelled F31 and F30 predoctoral fellowships and 66% of cancelled T34 undergraduate research awards. NIH terminated $56.8 million across these early-career programmes and a further $329.6 million in T32 institutional training grants. Separately, the AAMC tracker found 29% of all terminated grants were research training or career-development awards, versus 61% classified as standard research-and-development grants — a training-pipeline share roughly double what its overall funding weight would predict.

    Which fields and institutes were hit hardest

    By institute, the National Institute of Mental Health recorded the highest number of terminations (128 grants), followed by the National Institute on Minority Health and Health Disparities (77 grants), according to the JAMA Internal Medicine analysis. By dollar value, the National Institute of Allergy and Infectious Diseases lost the most funding ($505.9 million), with NIMHD second ($223.6 million).

    Clinical-trial data tell a parallel story: infectious-disease trials were the most affected topic area, at 14.4% of active trials disrupted, compared with 2.2% for neurologic and reproductive-health trials. Prevention-focused trials lost funding at more than four times the rate of basic-science trials (8.4% versus 2.0%). A separate PubMed Central review tallied at least 160 disrupted clinical trials spanning cancer and HIV/AIDS research, within a cumulative $3.8 billion in terminated NIH funding tracked across 2025.

    Which institutions and regions felt the impact

    Terminations touched 210 recipient institutions, but concentration was high: Columbia University recorded the most terminations of any single institution (157 grants) in the JAMA Internal Medicine sample. Geographically, trials based in the Northeast US were terminated at 6.3%, the highest of any US region, while multiregional US trials saw none. International trials lost funding at a higher rate than domestic ones (5.8% versus 3.4%), suggesting non-US collaborators carried a heavier share of the disruption than US-only projects.

    How the four tracking studies compare

    Reading the totals side by side clarifies why headline figures vary so widely in news coverage — each study samples a different window and a different data source, not a different underlying event.

    Study Snapshot window Grants terminated Value tracked Distinct focus
    Fregolent et al., PNAS (2026) Feb–Aug 2025 2,291 terminated; 1,534 frozen $2.45 billion Gender and career-stage breakdown
    Patel et al., JAMA Intern Med (2025) 28 Feb–8 Apr 2025 694 $1.81 billion Clinical-trial disruption by institute, topic, region
    AAMC tracker As of 5 May 2025 777 $1.9 billion Grant-type split (research vs training)
    Faiman et al., PubMed Central (2025) Cumulative, 2025 160+ clinical trials $3.8 billion Disease-area detail (cancer, HIV/AIDS)

    Answer-first Q&A

    Which universities get the most NIH funding?

    Johns Hopkins University has historically led all US institutions in total NIH support, with other top recipients including the University of Washington, Stanford and the University of Michigan. Institutions with large NIH portfolios are not automatically those hit hardest by terminations — Columbia University topped the termination count despite not leading in total funding received.

    How much did the Trump administration cut from the NIH budget?

    The administration’s fiscal year 2026 budget request proposed a roughly 40% reduction to NIH’s overall budget, alongside the direct termination of thousands of active awards earlier in 2025. Congress has not enacted a cut of that scale, and litigation over specific terminations remains ongoing into 2026.

    Who is considered the biggest funder of biomedical research?

    NIH is the largest single public funder of biomedical and behavioural research in the world, with an annual budget exceeding $47 billion. That scale is why even a partial termination round — a few thousand of the roughly 50,000 active awards — produced measurable, trackable disruption across the sector.

    What this means for institutions and funders

    For research administrators, the consistent finding across all four studies is that training and early-career awards carry outsized termination risk relative to their share of total NIH spending. Institutions with concentrated early-career or health-equity portfolios should treat independent trackers such as Grant Witness and NIH RePORTER as live risk-monitoring tools, not just retrospective journalism sources, when advising principal investigators on contingency funding and bridge support.

    The divergence between studies also carries a methodological lesson for anyone citing termination figures: always state the snapshot date and data source alongside any total, since “NIH grant terminations” without a date range can mean anywhere from 694 to over 2,291 awards depending on which tracking effort is cited.

    Outlook: restoration, litigation and ongoing tracking

    Not all terminations have proved final. Litigation challenging terminations tied to diversity, equity and gender-related research topics has led to court-ordered reinstatement of some awards during 2025, and appeals continue into 2026. Independent trackers, including Grant Witness and the Impact Project, are continuing to log both new terminations and restorations, meaning the totals in this piece are a snapshot, not an endpoint.

    Researchers and administrators should expect further peer-reviewed analyses through 2026 as tracking teams extend their datasets — particularly on downstream effects for publications, collaborations and workforce retention, which the PNAS authors flag as their next research target. For institutions building sponsored-research risk frameworks, this body of independent tracking work is now a more reliable source than any single news report of the terminations themselves.

  • NIH Grant Cancellation Legality Under 2 CFR 200

    NIH grant cancellation legality rests on 2 CFR 200.340: a grant may be terminated mid-cycle only if the recipient fails to comply with award terms, both parties consent, or the awarding agency determines the project no longer effectuates programme goals — and in every case NIH must issue written notice and preserve the recipient’s appeal rights before funding stops.

    A grant termination is the enforceable act of ending some or all of an active federal award before its approved project period expires, distinct from the routine non-renewal of a grant at the end of a competitive cycle. Understanding where that line sits — and what procedural protections apply on either side of it — is now a core competency for research administrators, not a hypothetical.

    Federal grant terminations are governed by the OMB Uniform Guidance codified at 2 CFR 200.340, which HHS incorporates into its own grants regulations and which NIH restates in Section 8.5.2 of the NIH Grants Policy Statement (“Suspension, Termination, and Withholding of Support”). This is an administrative-law standard, not a discretionary one: an awarding agency cannot terminate a grant for an unlisted reason, however compelling it finds that reason.

    NIH’s default posture, per its own policy statement, is to suspend a grant and give the recipient an opportunity for corrective action before proceeding to full termination — except where a serious deficiency or risk to health or safety justifies immediate termination.

    What grounds allow NIH to cancel a grant mid-cycle?

    2 CFR 200.340 recognises a closed, not open-ended, list of termination grounds. The Center for Science in the Public Interest’s litigation summary of APHA v. NIH describes these as “three limited circumstances” under the regulation.

    Ground Regulatory basis Typical trigger
    Recipient non-compliance 2 CFR 200.340(a)(1) Failure to meet award terms and conditions, financial mismanagement, or research misconduct findings
    Mutual agreement 2 CFR 200.340(a)(2) Recipient and NIH jointly agree the project is no longer viable (e.g. PI departure)
    Agency priorities / “for cause” 2 CFR 200.340(a)(4) NIH determines the award “no longer effectuates the program goals or agency priorities”

    The third ground is the one currently under judicial scrutiny. It gives the agency real latitude to align funding with shifting priorities, but that latitude is not unlimited: agency reasoning must still satisfy the Administrative Procedure Act’s bar on “arbitrary and capricious” action, meaning NIH must show a reasoned, non-conclusory basis tied to the individual award rather than a blanket, category-wide directive.

    What notice and appeal rights does 2 CFR 200 guarantee?

    Termination is not self-executing. 2 CFR 200.341 requires NIH to provide written notice specifying the reason for termination, the effective date, and whether the termination is full or partial. Where non-compliance is the stated ground, the notice must also disclose that the termination will be reported in the federal System for Award Management (SAM.gov), a public record that can affect an institution’s future funding eligibility.

    Recipients then have a two-tier route to challenge the decision:

    Stage Forum Typical deadline Scope of review
    First-level appeal NIH official named in the termination notice Per notice instructions Procedural and factual objections to the stated grounds
    Formal appeal HHS Departmental Appeals Board 30 days from final NIH decision Whether NIH followed its own regulations and notice requirements

    Disagreement over scientific merit is generally not a valid appeal ground; DAB review focuses on whether NIH complied with its own procedural rules, not on re-litigating peer review.

    How did 2025–26 litigation test these limits?

    The clearest real-world stress test of this framework is American Public Health Association v. NIH (D. Mass., No. 1:25-cv-10787). Beginning in February 2025, NIH terminated a large volume of active grants tied to categories the administration disfavoured, without individualised, award-specific justification.

    On 16 June 2025, District Judge William Young ruled the underlying directives and the resulting terminations arbitrary and capricious under the APA, finding the stated reasons “conclusory and bereft of reasoning.” His 23 June 2025 Partial Final Judgment declared the directives and terminations “of no effect, void, illegal, set aside, and vacated.” The First Circuit unanimously denied the government’s request to stay that judgment on 18 July 2025.

    On 21 August 2025, the Supreme Court issued a narrower, 5–4 emergency-docket ruling: it left the vacatur of the NIH directives in place, but held that district courts likely lack jurisdiction to order restoration of the terminated grants themselves, because such claims sound in contract and belong before the Court of Federal Claims under the Tucker Act. That split — policy directives reviewable in district court, individual grant restoration routed to a separate contract forum — is now the operative jurisdictional map for any institution challenging a termination. As of the case’s most recent public docket update, First Circuit oral argument on the merits appeal was calendared for 6 January 2026, with the outcome not yet reflected in publicly available case summaries at the time of writing.

    Separately, the Government Accountability Office found in August 2025 that NIH’s cancellation of roughly 1,800 grants violated the Impoundment Control Act of 1974, which requires the executive branch to obligate congressionally appropriated funds absent a formal rescission request to Congress. Harvard’s T.H. Chan School of Public Health, tracking the terminations independently, put the broader 2025 total at roughly 2,100 grants worth approximately $9.5 billion.

    Answer-first Q&A: what administrators are asking

    Are NIH grant terminations illegal?

    Not inherently. A termination is lawful when NIH cites one of the three grounds in 2 CFR 200.340, issues proper written notice, and grounds its reasoning in the specific award. A federal court found a 2025 wave of terminations unlawful specifically because NIH skipped individualised justification and relied on blanket, category-based directives instead.

    Can the government cancel a federal grant?

    Yes — federal agencies retain statutory authority to terminate grants “to the extent authorized by law,” including when an award no longer serves programme goals. That authority is bounded by the Administrative Procedure Act, the Impoundment Control Act’s restrictions on withholding appropriated funds, and the agency’s own termination regulations.

    How could researchers get a cancelled NIH grant restored?

    Institutions can pursue NIH’s internal appeal, then the HHS Departmental Appeals Board, or litigate under the APA in district court against the policy directive itself. Per the Supreme Court’s August 2025 ruling, restoration of the underlying funding obligation likely requires a separate contract claim at the Court of Federal Claims.

    How many NIH grants have been cancelled?

    Independent tracking by Harvard’s T.H. Chan School of Public Health documented roughly 2,100 grants worth approximately $9.5 billion terminated during 2025, a volume the litigation record describes as unprecedented against decades in which such terminations were “exceedingly rare.”

    What should research administrators do now?

    Three practical implications follow directly from the legal standard, independent of how any single case resolves:

    • Preserve every termination notice in full — the stated reason under 2 CFR 200.341 determines which appeal forum and deadline apply, and a vague or category-wide reason is itself a procedural defect worth flagging.
    • Track the SAM.gov disclosure trigger — a non-compliance-based termination notice generates a public record that can affect future eligibility, so institutions should confirm the correct ground was cited.
    • Route restoration claims correctly — the 2025 jurisdictional split means a policy challenge and a funds-restoration claim are no longer the same lawsuit, and misfiling in the wrong forum can cost months.

    The underlying legal standard has not changed: NIH still needs one of three grounds, still owes written notice, and recipients still retain a defined appeal path under 2 CFR 200. What 2025–26 litigation changed is the practical burden of proof NIH must meet to invoke the “agency priorities” ground, and the forum in which recipients must seek a remedy. Research administration offices that build both into their grant-monitoring workflow will be far better positioned than those relying on general awareness that “terminations are being challenged in court.”